Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Want to cut your energy bills? Here’s how five experts are doing it 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
SOUTH SAN FRANCISCO, Calif., March 11, 2016 -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker, Executive Vice President and Chief Business Officer, will present at the Barclays Global Healthcare Conference on Thursday, March 17, 2016 at 10:45 AM Eastern Daylight Time.
The live webcast will be accessible at http://investor.fiveprime.com/events.cfm or directly at https://cc.talkpoint.com/barc002/031516a_ae/?entity=133_M336FR1. Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and late preclinical development. For more information, please visit www.fiveprime.com.
CONTACT: Heather Rowe, Investor Relations 415-365-5737 [email protected]
